{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:20Z","timestamp":1786988120720,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T00:00:00Z","timestamp":1682812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejpb.2023.04.025","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T16:28:27Z","timestamp":1683044907000},"page":"6-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Putting square pegs in round holes: Why traditional pharmacokinetic principles cannot universally be applied to iron-carbohydrate complexes"],"prefix":"10.1016","volume":"188","author":[{"given":"Amy Barton","family":"Alston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinaldo","family":"Digigow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Fl\u00fchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias G.","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.04.025_b0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/joim.13004","article-title":"Iron deficiency anaemia revisited","volume":"287","author":"Cappellini","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejpb.2023.04.025_b0010","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/07853890.2020.1867323","article-title":"Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice","volume":"53","author":"Richards","year":"2021","journal-title":"Ann Med"},{"key":"10.1016\/j.ejpb.2023.04.025_b0015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2010.1.338","article-title":"Clinical use of intravenous iron: administration, efficacy, and safety","volume":"2010","author":"Auerbach","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ejpb.2023.04.025_b0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.V1.2.129.129","article-title":"Observations on the effect of massive doses of iron given intravenously to patients with hypochromic anemia","volume":"1","author":"Goetsch","year":"1946","journal-title":"Blood"},{"key":"10.1016\/j.ejpb.2023.04.025_b0025","article-title":"Iron Oxide Nanoparticle Formulations for Supplementation","volume":"19","author":"Pai","year":"2019","journal-title":"Met Ions Life Sci"},{"key":"10.1016\/j.ejpb.2023.04.025_b0030","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.3390\/ijms23042140","article-title":"Criticality of surface characteristics of intravenous iron-carbohydrate nanoparticle complexes: implications for pharmacokinetics and pharmacodynamics","volume":"23","author":"Funk F","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejpb.2023.04.025_b0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics3010012","article-title":"The pharmacokinetics and pharmacodynamics of iron preparations","volume":"3","author":"Geisser","year":"2011","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.04.025_b0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejpb.2022.03.006","article-title":"Tissue biodistribution of intravenous iron-carbohydrate nanomedicines differs between preparations with varying physicochemical characteristics in an anemic rat model","volume":"174","author":"Funk","year":"2022","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejpb.2023.04.025_b0045","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2020.250803","article-title":"Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways","author":"Garbowski","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ejpb.2023.04.025_b0050","article-title":"Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice","volume":"26","author":"Nikravesh","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2023.04.025_b0055","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40262-014-0218-2","article-title":"Evaluating plasma pharmacokinetics of intravenous iron formulations: judging books by their covers?","volume":"54","author":"Pai","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejpb.2023.04.025_b0060","first-page":"345","article-title":"The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose","volume":"60","author":"Funk","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejpb.2023.04.025_b0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/blood.V34.3.357.357","article-title":"Characteristics of iron dextran utilization in man","volume":"34","author":"Henderson","year":"1969","journal-title":"Blood"},{"key":"10.1016\/j.ejpb.2023.04.025_b0070","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.1365-2141.1999.01179.x","article-title":"Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography","volume":"104","author":"Beshara","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejpb.2023.04.025_b0075","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejpb.2023.04.025_b0080","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1093\/ndt\/gfq260","article-title":"Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds","volume":"25","author":"Toblli","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejpb.2023.04.025_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126493","article-title":"Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis","volume":"22","author":"Nemeth","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejpb.2023.04.025_b0090","article-title":"The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron-carbohydrate administration","author":"Garbowski","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejpb.2023.04.025_b0095","unstructured":"US_FDA, Drug Products, Including Biological Products, that Contain Nanomaterials Guidance for Industry, (2022)."},{"key":"10.1016\/j.ejpb.2023.04.025_b0100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jconrel.2022.12.049","article-title":"Orthogonal and complementary measurements of properties of drug products containing nanomaterials","volume":"354","author":"Simon","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.ejpb.2023.04.025_b0105","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejpb.2011.03.016","article-title":"A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications","volume":"78","author":"Jahn","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejpb.2023.04.025_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.984252","article-title":"Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory","volume":"13","author":"Dobrovolskaia","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejpb.2023.04.025_b0115","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1021\/ja107583h","article-title":"Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles","volume":"133","author":"Monopoli","year":"2011","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ejpb.2023.04.025_b0120","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1038\/s41467-021-25584-6","article-title":"The need for robust characterization of nanomaterials for nanomedicine applications","volume":"12","author":"Mahmoudi","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejpb.2023.04.025_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121073","article-title":"Injectable drug delivery systems of doxorubicin revisited: In vitro-in vivo relationships using human clinical data","volume":"608","author":"Modh","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ejpb.2023.04.025_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113829","article-title":"Nanomedicine at the crossroads - A quick guide for IVIVC","volume":"179","author":"Mast","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ejpb.2023.04.025_b0135","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17425247.2022.2081682","article-title":"Biopredictive tools for the development of injectable drug products","volume":"19","author":"Villa Nova","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.ejpb.2023.04.025_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26040831","article-title":"Exploring the Interplay between Drug Release and Targeting of Lipid-Like Polymer Nanoparticles Loaded with Doxorubicin","volume":"26","author":"Kovshova","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2023.04.025_b0145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2020.06.004","article-title":"A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release","volume":"153","author":"Nagpal","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejpb.2023.04.025_b0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejpb.2020.02.001","article-title":"Predicting human pharmacokinetics of liposomal temoporfin using a hybrid in silico model","volume":"149","author":"Jablonka","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejpb.2023.04.025_b0155","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2019.06.029","article-title":"Advanced in silico modeling explains pharmacokinetics and biodistribution of temoporfin nanocrystals in humans","volume":"308","author":"Jablonka","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.ejpb.2023.04.025_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041258","article-title":"Comparison of Compartmental and Non-Compartmental Analysis to Detect Biopharmaceutical Similarity of Intravenous Nanomaterial-Based Rifabutin Formulations","author":"Osipova","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.04.025_b0165","unstructured":"G. Price, D.A. Patel, Drug Bioavailability, in: StatPearls, StatPearls Publishing Copyright \u00a9 2022, StatPearls Publishing LLC., Treasure Island (FL), 2022."},{"key":"10.1016\/j.ejpb.2023.04.025_b0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00775-007-0297-8","article-title":"Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera","volume":"13","author":"Evans","year":"2008","journal-title":"J. Biol. Inorg. Chem."},{"key":"10.1016\/j.ejpb.2023.04.025_b0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yrtph.2018.05.014","article-title":"In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations","volume":"97","author":"Pai","year":"2018","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.ejpb.2023.04.025_b0180","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1592\/phco.27.3.343","article-title":"Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis","volume":"27","author":"Pai","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejpb.2023.04.025_b0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ajh.26374","article-title":"Plasma nontransferrin bound iron-nontransferrin bound iron revisited: Implications for systemic iron overload and in iv iron supplementation","volume":"97","author":"Cabantchik","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejpb.2023.04.025_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/nano8010010","article-title":"Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Biodistribution after Intravenous Dosing in Rats","volume":"8","author":"Beekman","year":"2017","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.ejpb.2023.04.025_b0195","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cmet.2015.09.006","article-title":"Ironing out Ferroportin","volume":"22","author":"Drakesmith","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.ejpb.2023.04.025_b0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jconrel.2019.02.030","article-title":"Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity","volume":"299","author":"Caputo","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.ejpb.2023.04.025_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2022.799341","article-title":"Nanomedicine Ex Machina: Between Model-Informed Development and Artificial Intelligence","volume":"4","author":"Villa Nova","year":"2022","journal-title":"Front Digit Health"},{"key":"10.1016\/j.ejpb.2023.04.025_b0210","unstructured":"European_Medicines_Agency, Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product 2015, https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-data-requirements-intravenous-iron-based-nano-colloidal-products-developed_en.pdf, accessed 12 December 2021."},{"key":"10.1016\/j.ejpb.2023.04.025_b0215","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0928-0987(98)00014-1","article-title":"Pharmacokinetics in organs and the intact body: model validation and reduction","volume":"7","author":"Weiss","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.04.025_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041258","article-title":"Quantification of Biopharmaceutical Inequivalence of Intravenous Nanomaterial-based Rifabutin Formulations using Compartmental and Non-Compartmental Analysis","author":"Osipova","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.04.025_b0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.vascn.2017.12.001","article-title":"Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations","volume":"91","author":"Span","year":"2018","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.ejpb.2023.04.025_b0230","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.vascn.2013.04.005","article-title":"Biodistribution and predictive hepatic gene expression of intravenous iron sucrose","volume":"68","author":"Elford","year":"2013","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"Suppl 2","key":"10.1016\/j.ejpb.2023.04.025_b0235","first-page":"S93","article-title":"Structure, chemistry, and pharmacokinetics of intravenous iron agents","volume":"15","author":"Danielson","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejpb.2023.04.025_b0240","article-title":"Probing Subcellular Iron Availability with Genetically Encoded Nitric Oxide Biosensors","volume":"12","author":"Sevimli","year":"2022","journal-title":"Biosensors (Basel)"},{"key":"10.1016\/j.ejpb.2023.04.025_b0245","doi-asserted-by":"crossref","first-page":"20568","DOI":"10.1021\/acsami.5b04290","article-title":"Protein Corona Influences Cellular Uptake of Gold Nanoparticles by Phagocytic and Nonphagocytic Cells in a Size-Dependent Manner","volume":"7","author":"Cheng","year":"2015","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.ejpb.2023.04.025_b0250","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2362.2009.02130.x","article-title":"Physicochemical properties of ferumoxytol, a new intravenous iron preparation","volume":"39","author":"Balakrishnan","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejpb.2023.04.025_b0255","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/clpt.2010.80","article-title":"Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects","volume":"88","author":"Pai","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejpb.2023.04.025_b0260","doi-asserted-by":"crossref","DOI":"10.7754\/Clin.Lab.2020.200742","article-title":"Revisiting Iron Metabolism, Iron Homeostasis and Iron Deficiency Anemia","volume":"67","author":"Saboor","year":"2021","journal-title":"Clin Lab"},{"key":"10.1016\/j.ejpb.2023.04.025_b0265","unstructured":"Venofer Prescribing Information."},{"key":"10.1016\/j.ejpb.2023.04.025_b0270","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/039139880602901106","article-title":"Determination of VIT 45 (IND#63,243 - American Regent) removal by closed loop in vitro hemodialysis system","volume":"29","author":"Manley","year":"2006","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.ejpb.2023.04.025_b0275","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1111\/bph.12604","article-title":"Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling","volume":"171","author":"Moss","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejpb.2023.04.025_b0280","doi-asserted-by":"crossref","first-page":"8350","DOI":"10.1016\/j.biomaterials.2010.07.045","article-title":"The kinetics of the tissue distribution of silver nanoparticles of different sizes","volume":"31","author":"Lankveld","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2023.04.025_b0285","doi-asserted-by":"crossref","first-page":"e1003299","DOI":"10.1371\/journal.pcbi.1003299","article-title":"A computational model of liver iron metabolism","volume":"9","author":"Mitchell","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ejpb.2023.04.025_b0290","doi-asserted-by":"crossref","first-page":"e1006060","DOI":"10.1371\/journal.pcbi.1006060","article-title":"Whole-body iron transport and metabolism: Mechanistic, multi-scale model to improve treatment of anemia in chronic kidney disease","volume":"14","author":"Sarkar","year":"2018","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ejpb.2023.04.025_b0295","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1039\/b816714c","article-title":"A general map of iron metabolism and tissue-specific subnetworks","volume":"5","author":"Hower","year":"2009","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.ejpb.2023.04.025_b0300","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejpb.2023.04.025_b0305","unstructured":"Monoferric Prescribing information, (September 2020)."},{"key":"10.1016\/j.ejpb.2023.04.025_b0310","unstructured":"INFeD Prescribing Information, (September 2020)."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:51:23Z","timestamp":1760547083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123001133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":62,"alternative-id":["S0939641123001133"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.04.025","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Putting square pegs in round holes: Why traditional pharmacokinetic principles cannot universally be applied to iron-carbohydrate complexes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}